EVALUATION OF NALMEFENE, AN ENDORPHIN ANTAGONIST, IN THE CONTROL OF APPETITE

该研究旨在评估纳美芬的疗效。 控制食欲的第三代纳洛酮。首字母 研究对象为Prader-Willi综合征患者。药物治疗 在三周内逐步增加到每毫克40毫克 天。这些患者随后在医院接受了为期两个月的跟踪调查。 门诊部，接受纳美芬治疗两周， 与安慰剂交替服用两周。最后一周的比赛 使用临床中心进行仔细的评估。没有任何影响 在5个Prader-Willi中的任何一个中都发现了食物摄入量方面的药物 综合症患者。协议已终止。

The study was designed to assess the efficacy of nalmefene--a third generation naloxone in the control of appetite. The initial subjects were Prader-Willi Syndrome patients. The medication was increased stepwise over a three week period to 40 mg per day. The patients were then followed for two months in the outpatient department, receiving nalmefene for two weeks, alternating with placebo for two weeks. A final week in the Clinical Center was used for careful evaluation. No effect of the medication was found on food intake in any of the 5 Prader-Willi syndrome patients. Protocol discontinued.